AstraZeneca Pharma India Limited (ASTRAZEN.BO)
INR 8871.7
(4.65%)
INR 8871.7
(4.65%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 12.95 Billion INR | 29.17% |
| 2022 | 10.02 Billion INR | 24.5% |
| 2021 | 8.05 Billion INR | -0.37% |
| 2020 | 8.08 Billion INR | -2.79% |
| 2019 | 8.31 Billion INR | 17.66% |
| 2018 | 7.06 Billion INR | 23.81% |
| 2017 | 5.71 Billion INR | 5.02% |
| 2016 | 5.43 Billion INR | -3.56% |
| 2015 | 5.63 Billion INR | 20.19% |
| 2014 | 4.69 Billion INR | -0.99% |
| 2013 | 4.73 Billion INR | 21.39% |
| 2012 | 3.9 Billion INR | -26.45% |
| 2011 | 5.3 Billion INR | -10.68% |
| 2010 | 5.94 Billion INR | 54.08% |
| 2009 | 3.85 Billion INR | 13.47% |
| 2008 | 3.39 Billion INR | 14.28% |
| 2007 | 2.97 Billion INR | 12.44% |
| 2006 | 2.64 Billion INR | 18.88% |
| 2005 | 2.22 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 3.87 Billion INR | 1.13% |
| 2023 Q2 | 3.11 Billion INR | 5.28% |
| 2023 Q1 | 2.95 Billion INR | 3.78% |
| 2023 Q4 | 3.83 Billion INR | 25.31% |
| 2023 Q3 | 3.05 Billion INR | -1.7% |
| 2023 FY | 12.95 Billion INR | 29.17% |
| 2022 Q3 | 2.49 Billion INR | 5.79% |
| 2022 Q4 | 2.84 Billion INR | 13.97% |
| 2022 Q1 | 2.32 Billion INR | 0.16% |
| 2022 Q2 | 2.36 Billion INR | 1.63% |
| 2022 FY | 10.02 Billion INR | 24.5% |
| 2021 Q3 | 2 Billion INR | 1.43% |
| 2021 Q4 | 2.31 Billion INR | 15.68% |
| 2021 FY | 8.05 Billion INR | -0.37% |
| 2021 Q1 | 1.75 Billion INR | -14.54% |
| 2021 Q2 | 1.97 Billion INR | 12.72% |
| 2020 Q2 | 2.09 Billion INR | 8.21% |
| 2020 FY | 8.08 Billion INR | -2.79% |
| 2020 Q4 | 2.05 Billion INR | 2.5% |
| 2020 Q3 | 2 Billion INR | -4.4% |
| 2020 Q1 | 1.93 Billion INR | -0.66% |
| 2019 Q1 | 2.04 Billion INR | 7.52% |
| 2019 Q2 | 2.08 Billion INR | 1.92% |
| 2019 Q3 | 2.23 Billion INR | 7.38% |
| 2019 Q4 | 1.94 Billion INR | -12.95% |
| 2019 FY | 8.31 Billion INR | 17.66% |
| 2018 FY | 7.06 Billion INR | 23.81% |
| 2018 Q3 | 2.15 Billion INR | 33.36% |
| 2018 Q4 | 1.9 Billion INR | -11.59% |
| 2018 Q1 | 1.61 Billion INR | 7.11% |
| 2018 Q2 | 1.61 Billion INR | -0.05% |
| 2017 Q4 | 1.5 Billion INR | 17.26% |
| 2017 Q3 | 1.28 Billion INR | -21.75% |
| 2017 Q2 | 1.64 Billion INR | 28.85% |
| 2017 Q1 | 1.27 Billion INR | 10.17% |
| 2017 FY | 5.71 Billion INR | 5.02% |
| 2016 Q2 | 1.38 Billion INR | -0.99% |
| 2016 Q4 | 1.15 Billion INR | -23.01% |
| 2016 Q3 | 1.5 Billion INR | 8.77% |
| 2016 FY | 5.43 Billion INR | -3.56% |
| 2016 Q1 | 1.39 Billion INR | 4.51% |
| 2015 FY | 5.63 Billion INR | 20.19% |
| 2015 Q4 | 1.33 Billion INR | -7.64% |
| 2015 Q3 | 1.44 Billion INR | 12.63% |
| 2015 Q2 | 1.28 Billion INR | 6.93% |
| 2015 Q1 | 1.2 Billion INR | -0.64% |
| 2014 Q4 | 1.2 Billion INR | 11.73% |
| 2014 FY | 4.69 Billion INR | -0.99% |
| 2014 Q1 | 1.25 Billion INR | 10.01% |
| 2014 Q2 | 1.14 Billion INR | -8.78% |
| 2014 Q3 | 1.08 Billion INR | -5.61% |
| 2013 Q4 | 1.14 Billion INR | -3.98% |
| 2013 FY | 4.73 Billion INR | 21.39% |
| 2013 Q1 | 1.25 Billion INR | 34.09% |
| 2013 Q2 | 1.15 Billion INR | -7.64% |
| 2013 Q3 | 1.18 Billion INR | 2.85% |
| 2012 Q3 | 1.04 Billion INR | 5.73% |
| 2012 Q2 | 992.28 Million INR | 8.73% |
| 2012 Q1 | 912.6 Million INR | -0.31% |
| 2012 FY | 3.9 Billion INR | -26.45% |
| 2012 Q4 | 933.2 Million INR | -11.05% |
| 2011 Q4 | 915.46 Million INR | -40.37% |
| 2011 Q3 | 1.53 Billion INR | 0.0% |
| 2011 FY | 5.3 Billion INR | -10.68% |
| 2010 FY | 5.94 Billion INR | 54.08% |
| 2009 FY | 3.85 Billion INR | 13.47% |
| 2008 FY | 3.39 Billion INR | 14.28% |
| 2007 FY | 2.97 Billion INR | 12.44% |
| 2006 FY | 2.64 Billion INR | 18.88% |
| 2005 FY | 2.22 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Achyut Healthcare Limited | 61.36 Million INR | -21010.496% |
| Ajanta Pharma Limited | 42.08 Billion INR | 69.218% |
| Alkem Laboratories Limited | 126.67 Billion INR | 89.773% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1091.412% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 78.804% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 95.487% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -173.655% |
| Brooks Laboratories Limited | 794.86 Million INR | -1529.882% |
| Divi's Laboratories Limited | 78.45 Billion INR | 83.486% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 95.359% |
| Eris Lifesciences Limited | 20.09 Billion INR | 35.518% |
| FDC Limited | 19.42 Billion INR | 33.321% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 89.033% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 43.258% |
| Granules India Limited | 45.06 Billion INR | 71.251% |
| Gufic Biosciences Limited | 8.06 Billion INR | -60.603% |
| Hester Biosciences Limited | 3.04 Billion INR | -325.397% |
| Indoco Remedies Limited | 17.89 Billion INR | 27.602% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -1.142% |
| Ipca Laboratories Limited | 76.22 Billion INR | 83.004% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -520.756% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -2469.4% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1141.702% |
| Laurus Labs Limited | 50.01 Billion INR | 74.099% |
| Lupin Limited | 200.1 Billion INR | 93.526% |
| Mankind Pharma Limited | 103.34 Billion INR | 87.464% |
| Medicamen Biotech Limited | 1.79 Billion INR | -622.524% |
| Medico Remedies Limited | 1.44 Billion INR | -793.958% |
| Megasoft Limited | 373.95 Million INR | -3364.419% |
| NATCO Pharma Limited | 40.02 Billion INR | 67.628% |
| Piramal Pharma Limited | 81.71 Billion INR | 84.145% |
| Sigachi Industries Limited | 3.98 Billion INR | -224.73% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -1614.905% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 97.329% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -23.225% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -399.734% |
| Unichem Laboratories Limited | 16.57 Billion INR | 21.834% |
| Windlas Biotech Limited | 6.3 Billion INR | -105.328% |
| ZIM Laboratories Limited | 3.67 Billion INR | -252.598% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 93.189% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -68.197% |
| RPG Life Sciences Limited | 5.82 Billion INR | -122.581% |
| Wanbury Limited | 5.75 Billion INR | -125.055% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -12.531% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -207.558% |
| Bal Pharma Limited | 3.39 Billion INR | -281.915% |
| Strides Pharma Science Limited | 40.51 Billion INR | 68.02% |
| Venus Remedies Limited | 5.91 Billion INR | -119.043% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 28.641% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 23.072% |
| Shilpa Medicare Limited | 11.51 Billion INR | -12.498% |
| Aarti Drugs Limited | 25.28 Billion INR | 48.764% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 38.86% |
| Suven Life Sciences Limited | 116.92 Million INR | -10979.63% |
| Ind-Swift Limited | 5.02 Billion INR | -157.833% |
| Valiant Laboratories Limited | 1.82 Billion INR | -611.606% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 62.817% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -4.614% |
| Themis Medicare Limited | 3.81 Billion INR | -239.356% |
| Hikal Limited | 17.84 Billion INR | 27.405% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 87.784% |
| Sequent Scientific Limited | 13.69 Billion INR | 5.417% |
| Novartis India Limited | 3.35 Billion INR | -286.645% |
| Wockhardt Limited | 27.89 Billion INR | 53.549% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 80.672% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -3135.969% |
| Neuland Laboratories Limited | 15.58 Billion INR | 16.878% |
| Morepen Laboratories Limited | 17.01 Billion INR | 23.877% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -739.223% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -251.478% |